SPH-BIOCAD (HK) Limited
3 clinical trials · Sponsor
◉ Watch SPH-BIOCAD (HK) Limited
| Record | Firm | Date |
|---|---|---|
| Evaluate Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of BCD-261 After Single Subcutaneous Injection in Healthy Chinese Volunteers (NCT07535775) | SPH-BIOCAD (HK) Limited | 2026-05-11 |
| To Evaluate the Efficacy and Safety of Netakimab in Chinese Patients With Moderate to Severe Plaque Psoriasis (NCT07008547) | SPH-BIOCAD (HK) Limited | 2024-07-30 |
| Evaluate the Efficacy, Safety, and Pharmacokinetic Profile and Immunogenicity of Subcutaneous Netakimab in Chinese Adult Patients With Active Ankylosing Spondylitis (NCT07277179) | SPH-BIOCAD (HK) Limited | 2023-03-20 |
Track SPH-BIOCAD (HK) Limited automatically
Every clearance here is in the API, with alerts when new ones post.